Replies to post #1570 on GTC Biotherapeutics (fka GTCB)

[keitern]

>>What's the incentive to invest if Atryn approval can't move the stock? Moral satisfaction?<<

Atryn approval did move the stock. The rest is beyond our control.

[Spice is nice]

At the end of 2002 GTC had 27,758,709 outstanding shares. At $4 they were awarded a market cap, or value of $111 million. Today GTC has -what- 120 outstanding or reserved shares?

Value rewarded today is closer to $140 million

Difference between then and now is an approval of a $10 million a year blockbuster and an assumed European acceptance of their platform. Simply put, although I would appreciate more, I will not bitch about todays value. Cheap in some respects, expensive in others. Only what GTC does going forward will change that.